Himadri Speciality Chemical Limited (HSCL) — Board Meeting

📢 Key Event
Board approved Q1 FY27 results and multi-crore capex plan for capacity expansion.

🔄 What Changed
Added Rs 128 crores capex for Anthraquinone/Carbazole expansion to 5300 MTPA (Phase 1 by Q2FY27), Rs 70 crores for CNT facility (commissioned by Q4FY27), and Rs 170 crores for Carbon Black (6000 MTPA by Q4FY28); standalone net profit rose to Rs 223.42 crores.

🔮 What's Next
Phase 1 capacity expansion to be completed by Q2FY27, Phase 2 by Q2FY28; CNT facility commissioned by Q4FY27; Carbon Black facility commissioned by Q4FY28.

💡 Investor Takeaway
The capex plan signals strategic capacity expansion in high-growth chemical segments, funded internally without dilution, while Q1 results show strong profitability with EPS of Rs 4.55.

The Board of Himadri Speciality Chemical Limited approved unaudited Q1 FY27 financial results (ended 30 June 2026) and announced capital expenditures totaling Rs 128 crores for Anthraquinone and Carbazole capacity expansion to 5300 MTPA (Phase 1 by Q2FY27), Rs 70 crores for India's first in-house Carbon Nano Tube (CNT) facility (commissioned by Q4FY27), and Rs 170 crores for Super Speciality Carbon Black production (6000 MTPA, commissioned by Q4FY28), all funded through internal accruals without altering overall capacity; the unaudited consolidated financial results show total income of Rs 1,488.19 crores, profit after tax of Rs 228.43 crores, and earnings per share of Rs 4.55, while the standalone results report revenue of Rs 1,274.26 crores and net profit of Rs 223.42 crores.

📄 View Original Announcement (PDF)

📊 Stock Analysis — HSCL ✨ Ask AI About This